Modification of post-myocardial infarction granulocyte-colony stimulating factor therapy with myelosuppressives

Circulation Journal

Volumn 71, Issue 4, 2007, Pages 580-590

  Misao, Yu ^a   Arai, Masazumi ^a   Ohno, Takamasa ^a   Ushikoshi, Hiroaki ^a   Onogi, Hirohito ^a   Kobayashi, Hiroyuki ^a   Takemura, Genzou ^a   Minatoguchi, Shinya ^a   Fujiwara, Takako ^b   Fujiwara, Hisayoshi ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO WOMEN'S UNIVERSITY   (Japan)

Author keywords

Cardiac repair; CXCR4 SDF 1 axis; G CSF; Myelosuppressives; Myocardial infarction

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD CELL COUNT; BONE MARROW CELL; CD34 SELECTION; CELL COUNT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENDOTHELIUM CELL; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART VENTRICLE REMODELING; IMMUNOHISTOCHEMISTRY; LEUKOCYTOSIS; MALE; NONHUMAN; RABBIT; STEM CELL; UPREGULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOOD CELL COUNT; CHEMOKINES, CXC; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; ENDOTHELIAL CELLS; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; HETEROCYCLIC COMPOUNDS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; RABBITS; RECEPTORS, CXCR4; VENTRICULAR REMODELING;

EID: 34047136019     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.580     Document Type: Article

References (28)

1. Minatoguchi S, Takemura G, Chen X, Wang N, Uno Y, Koda M, et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 2004; 109: 2572-2580.
2. Misao Y, Takemura G, Arai M, Ohno T, Onogi H, Takahashi T, et al. Importance of recruitment of bone marrow-derived CXCR4(+) cells in post-infarct cardiac repair mediated by G-CSF. Cardiovasc Res 2006; 71: 455-465.
3. Valgimigli M, Rigolin GM, Cittanti C, Malagutti P, Curello S, Percoco G, et al. Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: Clinical and angiographic safety profile. Eur Heart J 2005; 26: 1838-1845.
4. Suzuki K, Nagashima K, Arai M, Uno Y, Misao Y, Takemura G, et al. Effect of granulocyte colony-stimulating factor treatment at a low dose but for a long duration in patients with coronary heart disease: A pilot study. Circ J 2006; 70: 430-437.
5. Ripa RS, Jorgensen E, Wang Y, Thune JJ, Nilsson JC, Sondergaard L, et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: Result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 2006; 113: 1983-1992.
6. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 626-637.
7. Jantunen E, Putkonen M, Nousiainen T, Pelliniemi TT, Mahlamaki E, Remes K. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347-351.
8. +-cells. Circ J 2005; 69: 763-765.
9. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003; 62: 697-703.
10. +stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 2005; 110: 3213-3220.
11. Yi Y, Rana S, Turner JD, Gaddis N, Collman RG. CXCR-4 is expressed by primary macrophages and supports CCR5-independent infection by dual-tropic but not T-tropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72: 772-777.
12. Hendrix CW, Flexner C, MacFarland R, Giandomenico C, Fuchs EJ, Redpath G, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44: 1667-1673.
13. Takemura G, Ohno M, Hayakawa Y, Misao J, Kanoh M, Ohno A, et al. Role of apoptosis in the disappearance of infiltrated and proliferated interstitial cells after myocardial infarction. Circ Res 1998; 82: 1130-1138.
14. Ohno M, Takemura G, Ohno A, Misao J, Hayakawa Y, Minatoguchi S, et al. "Apoptotic" myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation: Analysis by immunogold electron microscopy combined with In situ nick end-labeling. Circulation 1998; 98: 1422-1430.
15. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687-694.
16. Takahama H, Minamino T, Hirata A, Ogai A, Asanuma H, Fujita M, et al. Granulocyte colony-stimulating factor mediates cardioprotection against ischemia/reperfusion injury via phosphatidylinositol-3-kinase/Akt pathway in canine hearts. Cardiovasc Drugs Ther 2006; 20: 159-165.
17. Ueda K, Takano H, Hasegawa H, Niitsuma Y, Qin Y, Ohtsuka M, et al. Granulocyte colony stimulating factor directly inhibits myocardial ischemia-reperfusion injury through Akt-endothelial NO synthase pathway. Arterioscler Throm Vasc Biol 2006; 26: 108-113.
18. Cesana C, Carlo-Stella C, Regazzi1 E, Garau D, Sammarelli G, Caramatti C, et al. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. Bone Marrow Transplant 1998; 21: 561-568.
19. Madjid M, Awan I, Willerson JT, Casscells W. Leukocyte count and coronary heart disease. J Am Coll Cardiol 2004; 44: 1945-1956.
20. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ Res 2001; 89: 201-210.
21. Spinale, FG. Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520-530.
22. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, et al. Inhibtion of plasminogen activators or matrix metalloproteinases prevents cardiac remodeling rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999; 5: 1135-1142.
23. Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Shokei-Kim, et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 2000; 102: 246-252.
24. Hayakawa K, Takemura G, Kanoh M, Li Y, Koda M, Kawase Y, et al. Inhibition of granulation tissue cell apoptosis during the subacute stage of myocardial infarction improves cardiac remodeling and dysfunction at the chronic stage. Circulation 2003; 108: 104-109.
25. Iwasaki H, Kawamoto A, Ishikawa M, Oyamada A, Nakamori S, Nishimura H, et al. Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recover after myocardial infarction. Circulation 2006; 113: 1311-1325.
26. Harada M, Qin Y, Takano H, Minamino T, Zou Y, Toko H, et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005; 11: 305-311.
27. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, Lomberd-Bohas C, Duperret S, Belkhiria M, et al. Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 2006; 25: 305-309.
28. Morandi P, Ruffini PA, Benvenuto GM, Raimondi R, Fosser V. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005; 35: 323-334.